Cancer Science & Research


Clinical Outcomes of Small Cell Carcinoma of Bladder: A Single Institutional Experience

Rasha Mohamed Abdel Latif.

Background: Small cell carcinoma (SCC) is a rare disease, lung is the commonest site. In the urinary bladder SCC represent less than 1% of tumors affecting bladder.

Objectives: In this study we tried to evaluate clinic-pathological data of cases with small cell carcinoma of bladder (SCCB), highlight the different lines of treatment used in our department and calculate overall survival (OS) and disease-free survival (DFS).

Patients and Methods: This are a retrospective study included patients diagnosed with SCC of bladder (SCCB), data collected from files and computer based of patients attended to Clinical Oncology & Nuclear Medicine department in the period from January 2006 to December 2016.

Results: The study included 19 patients with mean age 64.5 ± 7.2, male: female ratio 3.75:1. Gross hematuria presented in 89.5%, mean size was 4.7±1.6 and tumor located on 47.4% on lateral wall. Stage III was the commonest in 52.6%. Pure small cell diagnosed in only 5 patients (26.3%). Seven patients (36.8%) treated with radical cystectomy, fourteen (73.7%) received chemotherapy, vepsid-platinol was the commonest regimen used (36.8%). Radiotherapy used in 9 patients (47.4%). The median OS and DFS were 23 and 12months respectively. Radical cystectomy associated with better survival, while chemotherapy did not show benefit.

Conclusion: The SCCB is a rare disease, presented in advanced stage, so require radical treatment because it is associated with early metastasis. However, as reported surgery associated with better survival specially with combined modality. More advanced researches are needed with more analysis of different lines of treatment and its combination for improvement of survival.

View pdf